Overview
The Iliev Lab Home Page: http://ilievlab.weill.cornell.edu/
The mammalian gastrointestinal tract is colonized by diverse commensal microbial communities consisting of bacteria, fungi and viruses. The Iliev Laboratoty laboratory studies the interaction between this commensal microbiota and the immune cells at the mucosal surfaces of the body. Our research is specifically focused on understanding the functional consequences of fungal microbiota (mycobiota) composition and metabolism to the host's immunity and to bacterial populations in the gut. In this effort, we have developed in vivo models, model fungal strains and bioinformatics pipelines that aid with tools to study the role of gut fungi in mucosal immunity during health and during conditions, such as inflammatory bowel disease, allergy and immunosuppression, in which fungi can contribute to pathologies.
Research Areas:
Immunity to Mucosa-Associated FungiDiverse fungal communities colonize all mucosal surfaces of the body. While some commensal fungi can be opportunistic pathogens and can lead to serious infections upon a bridge of the mucosal barriers, evidence coming from the lab suggests that a balanced fungal community is necessary for the maintenance of intestinal health.
The Iliev Laboratory is specifically interested in molecular mechanisms by which fungi interact with gut-resident phagocytes and polarize protective adaptive immune responses. Using in vivo murine models lacking immune arms and antifungal receptors, we study the interaction of commensal fungi with the gut immune system during steady state and during colitis. Our final goal is to understand how this interaction is regulated and provide strategies to manipulate these pathways.
Characterization of Intestinal Fungal Communities (Mycobiota) and Their Interaction with Bacteria
Highlights
- 1
- 2Nature · 2022
- 3
Publications
Funding
Active
10 grants- PIImmune mechanisms of fungal influence on the gut-brain axis.National Institute of Allergy and Infectious Diseases · 2026–2031R01AI198729-01
- MPIInvestigation of gut microbiota metabolite-mediated transkingdom interactions with fungiNational Institute of Allergy and Infectious Diseases · 2024–2029R01AI178683-03
- PIGASTROINTESTINAL FUNGAL INFECTIONS: WHAT SHOULD THE IMMUNE SYSTEM WATCH FOR?Burroughs Wellcome Fund · 2020–2027BWF 1020451
- MPILloyd J. Old STAR ProgramCancer Research Institute, Inc. · 2022–2027CRI 222556-2
- PIFungal-bacterial interactions: an opportunity for novel treatment of Ulcerative Colitis.Kenneth Rainin Foundation · 2024–2027KRF 20260154
- PIRegulation and function of mucosal IgA immune responses to mycobiota in the gut.National Institute of Allergy and Infectious Diseases · 2021–2027R01AI163007-05
- PICommensal fungal communities in the regulation of immunity and intestinal inflammationNational Institute of Diabetes and Digestive and Kidney Diseases · 2017–2027· 2 renewalsR01DK113136-09
- PIMononuclear phagocyte networks in mycobiota regulation and antifungal immunity.National Institute of Diabetes and Digestive and Kidney Diseases · 2020–2027R01DK121977-05
- PITargeting the mycobiome in patients with Crohn’s DiseaseThe Leona M. and Harry B. Helmsley Charitable Trust · 2023–20272311-06390
Completed grants (14)
- PIAward #28646 - Identifying mycobiome-derived enteric neuromodulatorsResearch Corporation for Science Advancement · 2022–2024RCSA 28646
- Co-IMechanistic Investigation of Gut Mycobiota in the Regulation of Lung Immunity and DiseaseNational Heart, Lung, and Blood Institute · 2022–2023
- PITargeting the mycobiome in Crohn's Disease: development of targeting strategy and biomarkers for prospective clinical trialLeona M. and Harry B. Helmsley Charitable Trust, The · 2019–2023HCT 2004-03879
- PIInvestigation of commensal bacteria-produced metabolites with activity towards mycobiota.National Institute of Allergy and Infectious Diseases · 2019–2022R21AI146957-02
- KPRegulation of the mycobiota and intestinal inflammation via production of antifungal metabolites by commensal bacteriaNational Institute of Diabetes and Digestive and Kidney Diseases · 2019–2022FellowshipF32DK120228-01
- PIExploring immunity to fungal microbiota in IBDCrohn's and Colitis Foundation of America · 2019–2021CCFA 6609964
- KPImpact of commensal fungi on the response to immunosuppressive therapy in intestinal diseases Impact of commensal fungi on the response to immunosuppressive therapy in intestinal diseases.Charles H. Revson Foundation Inc. · 2019–2021Fellowship19-29
- PISYNERGY AWARDS PROGRAM FOR IBD RESEARCHKenneth Rainin Foundation · 2019–20202017-3131 Phase III
- PIInnate Immune Regulation of Mycobiota During Health and DiseaseNational Institute of Allergy and Infectious Diseases · 2018–2019R56AI137157-01
- PIThe Kenneth Rainin Foundation Synergy Award Program for IBD Research. Renewal grantKenneth Rainin Foundation · 2018–20192017-3131 Phase II
- PIMechanisms of Protection by Commensal Fungi in ColitisNational Institute of Diabetes and Digestive and Kidney Diseases · 2016–2018R00DK098310-05
- PIThe Role of Mycobiota During Immunomodulatory Therapy for Inflammatory Bowel DiseaseKenneth Rainin Foundation · 2015–20182016-3058
- PIImpact of immunosuppression therapy on commensal fungi and intestinal diseaseNational Institute of Allergy and Infectious Diseases · 2016–2018R21AI123819-02
- PIMechanisms of Protection by Commensal Fungi in ColitisNIDDK · 2014–2016 · via NIH RePORTERK99DK098310-02
Honors & distinctions
- Investigators in the Pathogenesis of Infectious Disease (PATH) Award · Burroughs Wellcome Fund · 2020
Clinical research
Active
1 study- PINCT06433310Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot StudyPHASE4 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)Gut Microbiome; Gut Health; Dietary Supplement; L-Phenylalanine; Phenylpropionic Acid
Available technologies
- Treatment of Fungal-Associated Irritable Bowel Disease Using IL-1 Inhibitors10153Application filedPoC DataPMID 35296857
News mentions
- Antifungal Therapy Shows Potential for IBD Patients with Candida OvergrowthSeptember 1, 2026
A commonly used systemic antifungal medication may help reduce symptoms in a subset of patients with inflammatory bowel disease (IBD) by restoring a healthier gut microbiome, according to a preliminary study by Weill Cornell Medicine investigators.
- What a Gut Fungus Reveals About Symbiosis and AllergyNovember 27, 2024
A fungus discovered in the mouse stomach may hold a key to fungal evolution within the gastrointestinal tract, according to new research led by Weill Cornell Medicine investigators.
- Gut Fungi's Lasting Impact on Severe COVID-19 Immune ResponseOctober 23, 2023
Certain gut-dwelling fungi flourish in severe cases of COVID-19, amplifying the excessive inflammation that drives this disease while also causing long-lasting changes in the immune system, according to a new study led by investigators at Weill Cornell Medicine and NewYork-Presbyterian.
- Grant Awarded to Investigate Antifungal Therapies in Crohn’s PatientsJune 15, 2023
Dr. Iliyan D. Iliev, an associate professor of immunology in medicine in the Division of Gastroenterology and Hepatology, co-director of the Microbiome Core and a member of the Jill Roberts Institute for Research in Inflammatory Bowel Disease (IBD) at Weill Cornell Medicine, is the lead investigator on a grant to Weill Cornell Medicine from The Leona M. and Harry B. Helmsley Charitable Trust to target pathogenic fungi in patients with Crohn’s disease.
- Fungal Association with Tumors May Predict Worse OutcomesSeptember 29, 2022
The presence of some fungal species in tumors predicts—and may even help drive—worse cancer outcomes, according to a study from Weill Cornell Medicine and Duke University researchers.
Show 8 more mentions
- Awards and Honors – July 29, 2022July 29, 2022
Awards, honors, prizes and achievements for the month of July.
- Grant Funds Study of the Role of Fungi in Cancer Development and ImmunotherapyJuly 18, 2022
Dr. Iliyan D. Iliev, an associate professor of immunology in medicine in the Division of Gastroenterology and Hepatology and a member of the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine, has been awarded a five-year, $1.25 million CRI Lloyd J. Old STAR (Scientists Taking Risks) Program grant from Cancer Research Institute (CRI).
- Toxin-producing Yeast Strains in Gut Fuel IBDMarch 16, 2022
Individual Candida albicans yeast strains in the human gut are as different from each other as the humans that carry them, and some C. albicans strains may damage the gut of patients with inflammatory bowel disease (IBD), according to a new study from researchers at Weill Cornell Medicine.
- Preclinical Study Finds Gut Fungi Influence Neuroimmunity and BehaviorFebruary 16, 2022
A specific group of fungi residing in the intestines can protect against intestinal injury and influence social behavior, according to new preclinical research by scientists at Weill Cornell Medicine.
- Antibodies Help Keep Harmful Forms of Gut Fungi in CheckNovember 22, 2021
Antibody protection against harmful forms of fungi in the gut may be disrupted in some patients with Crohn’s disease—a condition caused by chronic inflammation in the bowel—according to a new study by Weill Cornell Medicine investigators.
- Fungi in the Gut Prime Immunity Against InfectionFebruary 5, 2021
Common fungi, often present in the gut, teach the immune system how to respond to their more dangerous relatives, according to new research from scientists at Weill Cornell Medicine.
- Weill Cornell Medicine Scientist Receives Pathogenesis of Infectious Disease AwardNovember 11, 2020
Dr. Iliyan Iliev, an associate professor of immunology in medicine in the Division of Gastroenterology and Hepatology and a scientist in the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine, has been awarded the Investigators in the Pathogenesis of Infectious Disease (PATH) award by the Burroughs Wellcome Fund.
- Fungus in Gut May Explain Why Some Ulcerative Colitis Patients Benefit from Fecal TransplantMay 14, 2020
Higher levels of a type of fungus in the gut are associated with better outcomes for patients with a type of inflammatory bowel disease called ulcerative colitis who are treated with gut microbes from healthy donors.
Media highlights
- 5 Gastroenterology Headlines You Missed In September 2026HCP Live · October 6, 2026
- Targeting Gut Candida To Treat IBD, With Iliyan D. Iliev, PhDHCP Live · September 25, 2026
- How Candida Moves From Mouth To Gut In IBD, With Iliyan D. Iliev, PhDHCP Live · September 21, 2026
- Antifungal Therapy Eased IBD Activity, With Iliyan D. Iliev, PhDHCP Live · September 21, 2026
- Antifungal Therapy Shows Potential For IBD Patients With Candida Overgrowth: StudyMedical Dialogues · September 3, 2026
Show 1 more mention
- Antifungal Drug May Ease IBD Disease ActivityLabRoots · September 2, 2026
Mentoring
- XLXin LiPostdoc mentee · 2021–2023
- WLWoan-Yu LinImmunology & Microbial Pathogenesis · Class of 2024
- IDItai DoronPhysiology, Biophysics & Systems Biology (PhD) · Class of 2022
- GAGuilhermina Augusta CarrichePostdoc mentee · 2020–2022
- HGHanxing GaoImmunology & Microbial Pathogenesis (PhD) · Class of 2024
- XMXiaojian MaPostdoc mentee · 2022–2024
External relationships
Speaker/Lecturer
American Gastroenterological Association